SG11201400616YA - Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. - Google Patents

Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.

Info

Publication number
SG11201400616YA
SG11201400616YA SG11201400616YA SG11201400616YA SG11201400616YA SG 11201400616Y A SG11201400616Y A SG 11201400616YA SG 11201400616Y A SG11201400616Y A SG 11201400616YA SG 11201400616Y A SG11201400616Y A SG 11201400616YA SG 11201400616Y A SG11201400616Y A SG 11201400616YA
Authority
SG
Singapore
Prior art keywords
treatment
kinase inhibitors
hyperproliferative diseases
bub1 kinase
benzylindazoles
Prior art date
Application number
SG11201400616YA
Other languages
English (en)
Inventor
Marion Hitchcock
Anne Mengel
Vera Pütter
Gerhard Siemeister
Antje Margret Wengner
Hans Briem
Knut Eis
Volker Schulze
Amaury Ernesto Fernandez-Montalvan
Stefan Prechtl
Simon Holton
Jörg Fanghänel
Philip Lienau
Cornelia Preusse
Mark Jean Gnoth
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of SG11201400616YA publication Critical patent/SG11201400616YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01HNEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H6/00Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
    • A01H6/36Ericaceae, e.g. azalea, cranberry or blueberry
    • A01H6/368Vaccinium, e.g. cranberry, blueberry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201400616YA 2011-10-06 2012-10-04 Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. SG11201400616YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11184061 2011-10-06
PCT/EP2012/069562 WO2013050438A1 (en) 2011-10-06 2012-10-04 Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.

Publications (1)

Publication Number Publication Date
SG11201400616YA true SG11201400616YA (en) 2014-09-26

Family

ID=46968229

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201400616YA SG11201400616YA (en) 2011-10-06 2012-10-04 Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.

Country Status (38)

Country Link
US (3) US20140249133A1 (de)
EP (1) EP2763982B1 (de)
JP (1) JP6140170B2 (de)
KR (1) KR102007056B1 (de)
CN (1) CN103974948B (de)
AP (1) AP3847A (de)
AR (1) AR088449A1 (de)
AU (1) AU2012320582B2 (de)
BR (1) BR112014008045A2 (de)
CA (1) CA2851037A1 (de)
CO (1) CO6930363A2 (de)
CR (1) CR20140161A (de)
CU (1) CU20140043A7 (de)
CY (1) CY1120318T1 (de)
DK (1) DK2763982T3 (de)
DO (1) DOP2014000062A (de)
EA (1) EA201400412A1 (de)
EC (1) ECSP14013284A (de)
ES (1) ES2665036T3 (de)
GT (1) GT201400063A (de)
HK (1) HK1200449A1 (de)
HR (1) HRP20180546T1 (de)
HU (1) HUE037154T2 (de)
IL (1) IL231591A (de)
LT (1) LT2763982T (de)
MX (1) MX361279B (de)
NO (1) NO2763982T3 (de)
PE (1) PE20141203A1 (de)
PL (1) PL2763982T3 (de)
PT (1) PT2763982T (de)
RS (1) RS57099B1 (de)
SG (1) SG11201400616YA (de)
SI (1) SI2763982T1 (de)
TN (1) TN2014000138A1 (de)
TW (1) TWI588141B (de)
UA (1) UA111754C2 (de)
UY (1) UY34374A (de)
WO (1) WO2013050438A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
JP6141866B2 (ja) 2011-12-21 2017-06-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換ベンジルピラゾール類
ES2620316T3 (es) * 2012-05-11 2017-06-28 Bayer Pharma Aktiengesellschaft Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer
WO2014147204A1 (en) * 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
WO2014147144A1 (en) * 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
JP2016514718A (ja) * 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト 3−ヘテロアリール置換インダゾール類
EP3010911A1 (de) * 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Heteroarylsubstituierte pyrazole
US20160151370A1 (en) * 2013-06-21 2016-06-02 Bayer Pharma Aktiengesellschaft Substituted Benzylpyrazoles
US20160145267A1 (en) 2013-06-21 2016-05-26 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
ES2652305T3 (es) * 2013-06-21 2018-02-01 Bayer Pharma Aktiengesellschaft Pirazoles heteroaril sustituidos
US9765058B2 (en) 2013-06-21 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
CN105764893A (zh) * 2013-10-30 2016-07-13 拜耳制药股份公司 杂芳基取代的吡唑
WO2015193339A1 (en) * 2014-06-17 2015-12-23 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107074825A (zh) * 2014-09-19 2017-08-18 拜耳制药股份公司 作为bub1激酶抑制剂的苄基取代的吲唑类化合物
US20170305882A1 (en) * 2014-09-19 2017-10-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
EP3194378A1 (de) * 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzylsubstituierte indazole
CN107001331A (zh) * 2014-09-19 2017-08-01 拜耳制药股份公司 作为bub1抑制剂的苄基取代的吲唑
GB201419264D0 (en) * 2014-10-29 2014-12-10 Karus Therapeutics Ltd Compounds
UA122221C2 (uk) 2015-01-28 2020-10-12 Байєр Фарма Акцієнгезелльшафт 4Н-ПІРОЛО[3,2-c]ПІРИДИН-4-ОНОВІ ПОХІДНІ
US10106501B2 (en) * 2015-06-09 2018-10-23 Abbvie Inc. Nuclear receptor modulators
US10227299B2 (en) 2015-06-17 2019-03-12 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
CA3008393A1 (en) * 2015-12-16 2017-06-22 Bayer Pharma Aktiengesellschaft Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
KR102048050B1 (ko) * 2019-08-29 2020-01-22 대한민국 Adb-푸비나카의 대사체 합성 방법
CN110684016A (zh) * 2019-09-27 2020-01-14 上海应用技术大学 一种含氟的azd9291衍生物及其制备方法和应用
CA3196712A1 (en) 2020-09-23 2022-03-31 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
TW202229282A (zh) 2020-09-30 2022-08-01 美商史考皮恩治療有限公司 治療癌症之方法
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5470862A (en) 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds
BR9712523A (pt) 1996-10-14 2000-05-09 Bayer Ag Novos derivados de pirazol heterociclilmetil-substituìdos
DE19834047A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19846514A1 (de) * 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
JP4286146B2 (ja) 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピラゾール系調節剤
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
US20040132730A1 (en) 2002-09-10 2004-07-08 Jonathan Axon Inhibitors of TGFbeta
DE10244810A1 (de) * 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
WO2007038613A2 (en) 2005-09-26 2007-04-05 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20080242681A1 (en) 2004-01-22 2008-10-02 Altana Pharma Ag N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors
WO2007065010A2 (en) * 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
WO2008141731A2 (en) 2007-05-18 2008-11-27 Bayer Healthcare Ag Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
JP2010111624A (ja) * 2008-11-06 2010-05-20 Shionogi & Co Ltd Ttk阻害作用を有するインダゾール誘導体
ES2630026T3 (es) 2008-12-18 2017-08-17 Nerviano Medical Sciences S.R.L. Derivados indazólicos sustituidos activos como inhibidores de cinasa
US20120232062A1 (en) 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
PT2504334E (pt) 2009-11-27 2014-12-03 Bayer Ip Gmbh Processo para a purificação de metil-{4,6-diamino-2-[1-(2- fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5- il}metilcarbamato
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2829790C (en) 2010-03-30 2018-06-05 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
BR112012033341B1 (pt) 2010-06-30 2022-08-23 Cyclerion Therapeutics, Inc Estimulantes de sgc
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
JP6141866B2 (ja) 2011-12-21 2017-06-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換ベンジルピラゾール類
EP2797915B1 (de) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-Benzyl-3-(Oxazol/Thiazol)-5-(Pyrimidin-2-yl)-1(H)-Pyrazol-Derivate als Stimulatoren der löslichen Guanylat-Cyclase (sGC) zur Behandlung von Bluthochdruck und Herzversagen
ES2620316T3 (es) 2012-05-11 2017-06-28 Bayer Pharma Aktiengesellschaft Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
CA2885645A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014047662A2 (en) 2012-09-24 2014-03-27 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
WO2014147204A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
JP2016514718A (ja) 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト 3−ヘテロアリール置換インダゾール類
WO2014147144A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted indazoles
US9765058B2 (en) 2013-06-21 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
ES2652305T3 (es) 2013-06-21 2018-02-01 Bayer Pharma Aktiengesellschaft Pirazoles heteroaril sustituidos
US20160145267A1 (en) 2013-06-21 2016-05-26 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
US20160151370A1 (en) 2013-06-21 2016-06-02 Bayer Pharma Aktiengesellschaft Substituted Benzylpyrazoles
EP3010911A1 (de) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Heteroarylsubstituierte pyrazole
CN105764893A (zh) 2013-10-30 2016-07-13 拜耳制药股份公司 杂芳基取代的吡唑
CN107074825A (zh) 2014-09-19 2017-08-18 拜耳制药股份公司 作为bub1激酶抑制剂的苄基取代的吲唑类化合物
CN107001331A (zh) 2014-09-19 2017-08-01 拜耳制药股份公司 作为bub1抑制剂的苄基取代的吲唑
EP3194378A1 (de) 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzylsubstituierte indazole
US20170305882A1 (en) 2014-09-19 2017-10-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
WO2017148995A1 (en) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity
WO2017157991A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases
WO2017157992A1 (en) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors

Also Published As

Publication number Publication date
SI2763982T1 (en) 2018-06-29
GT201400063A (es) 2015-12-07
NZ623098A (en) 2016-09-30
CN103974948A (zh) 2014-08-06
AR088449A1 (es) 2014-06-11
CU20140043A7 (es) 2014-08-28
PE20141203A1 (es) 2014-10-01
EA201400412A1 (ru) 2014-08-29
MX361279B (es) 2018-12-03
US20190284206A1 (en) 2019-09-19
UY34374A (es) 2013-05-31
ES2665036T3 (es) 2018-04-24
JP6140170B2 (ja) 2017-05-31
RS57099B1 (sr) 2018-06-29
TN2014000138A1 (en) 2015-09-30
TWI588141B (zh) 2017-06-21
TW201321370A (zh) 2013-06-01
AP2014007533A0 (en) 2014-03-31
CA2851037A1 (en) 2013-04-11
CY1120318T1 (el) 2019-07-10
UA111754C2 (uk) 2016-06-10
US20140249133A1 (en) 2014-09-04
US10604532B2 (en) 2020-03-31
IL231591A (en) 2016-09-29
WO2013050438A1 (en) 2013-04-11
ECSP14013284A (es) 2014-05-31
CR20140161A (es) 2014-06-03
EP2763982B1 (de) 2018-01-10
US10266548B2 (en) 2019-04-23
IL231591A0 (en) 2014-05-28
NO2763982T3 (de) 2018-06-09
DK2763982T3 (en) 2018-04-23
PT2763982T (pt) 2018-04-16
DOP2014000062A (es) 2014-07-15
US20170260198A1 (en) 2017-09-14
KR20140075775A (ko) 2014-06-19
HRP20180546T1 (hr) 2018-05-04
HK1200449A1 (en) 2015-08-07
KR102007056B1 (ko) 2019-08-02
LT2763982T (lt) 2018-04-25
AU2012320582B2 (en) 2017-06-15
MX2014004122A (es) 2014-06-04
AU2012320582A1 (en) 2014-04-17
PL2763982T3 (pl) 2018-07-31
CN103974948B (zh) 2017-07-28
BR112014008045A2 (pt) 2017-04-11
JP2014531465A (ja) 2014-11-27
CO6930363A2 (es) 2014-04-28
EP2763982A1 (de) 2014-08-13
HUE037154T2 (hu) 2018-08-28
AP3847A (en) 2016-09-30

Similar Documents

Publication Publication Date Title
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
HUS2200017I1 (hu) Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
IL238571A0 (en) Broton tyrosine kinase inhibitors, preparations containing them and their uses
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
HK1205500A1 (en) Kinase inhibitors for the treatment of cancer
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer